Literature DB >> 11790786

Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.

M Margarida Bernardo1, Stephen Brown, Zhi-Hong Li, Rafael Fridman, Shahriar Mobashery.   

Abstract

Gelatinases have been shown to play a key role in angiogenesis and tumor metastasis. Small molecular weight synthetic inhibitors for these enzymes are highly sought for potential use as anti-metastatic agents. Virtually all of the known inhibitors of matrix metalloproteinases (MMPs) are broad spectrum. We report herein the synthesis and kinetic characterization of two compounds, 4-(4-phenoxyphenylsulfonyl)butane-1,2-dithiol (compound 1) and 5-(4-phenoxyphenylsulfonyl)pentane-1,2-dithiol (compound 2), that are potent and selective gelatinase inhibitors. These compounds are slow, tight-binding inhibitors of gelatinases (MMP-2 and MMP-9) with K(i) values in the nanomolar range. In contrast, competitive inhibition of the catalytic domain of membrane-type 1 metalloproteinase (MMP-14(cat)) with comparable K(i) values (K(i) approximately 200 nm) was observed. Binding to stromelysin (MMP-3) was substantially weaker, with K(i) values in the micromolar range (K(i) approximately 10 microm). No binding to matrilysin (MMP-7) and collagenase 1 (MMP-1) was detected at inhibitor concentrations up to 60 microm. We have previously shown that synthetic MMP inhibitors work synergistically with TIMP-2 in the promotion of pro-MMP-2 activation by MT1-MMP in a process that depends on the affinity of the inhibitor toward MT1-MMP. It is shown herein that the dithiols are significantly less efficient (>100-fold) than marimastat, a broad-spectrum MMP inhibitor, in enhancing pro-MMP-2 activation in cells infected to express MT1-MMP, consistent with the lower affinity of the dithiols toward MT1-MMP. Thus, in contrast to broad-spectrum MMP inhibitors, the dithiols are less likely to promote MT1-MMP-dependent pro-MMP-2 activation in the presence of TIMP-2, while maintaining their ability to inhibit active MMP-2 effectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790786     DOI: 10.1074/jbc.M111021200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

2.  Role of MMP2 and MMP9 in TRPV4-induced lung injury.

Authors:  Patricia C Villalta; Petra Rocic; Mary I Townsley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-08-22       Impact factor: 5.464

Review 3.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 5.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 6.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

7.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

8.  Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17.

Authors:  Melba Muñoz; Markus M Heimesaat; Kerstin Danker; Daniela Struck; Uwe Lohmann; Rita Plickert; Stefan Bereswill; André Fischer; Ildikò Rita Dunay; Kerstin Wolk; Christoph Loddenkemper; Hans-Willi Krell; Claude Libert; Leif R Lund; Oliver Frey; Christoph Hölscher; Yoichiro Iwakura; Nico Ghilardi; Wenjun Ouyang; Thomas Kamradt; Robert Sabat; Oliver Liesenfeld
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

9.  Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.

Authors:  Jason C Kwan; Erika A Eksioglu; Chen Liu; Valerie J Paul; Hendrik Luesch
Journal:  J Med Chem       Date:  2009-09-24       Impact factor: 7.446

10.  Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.

Authors:  Etelka Farkas; Yiffat Katz; Sudhakar Bhusare; Reuven Reich; Gerd-Volker Röschenthaler; Martin Königsmann; Eli Breuer
Journal:  J Biol Inorg Chem       Date:  2004-02-05       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.